SUBSCRIBE TO OUR RSS
Biggest Market Movers
The Burrill Report
January 13, 2012
[Please login to post comments]
Sage Therapeutics Scores $90M in Upsized IPO
Strong demand raises confidence for more such deals.
AbbVie and Shire Agree to $54B Union
Chicago-based AbbVie will move headquarters to U.K. in biggest tax inversion deal to date.
FDA Approves Ruconest to Treat Rare Genetic Disease
Salix and Pharming’s new biologic is produced in the milk of transgenic rabbits.
The Changing Patent Landscape for Genome 2.0
Podcast: July 21, 2014
Genetic Risk for Autism Mostly from Common Gene Variants
Study estimates roles of heritability, mutations, and environment as causing the disorder.
AbbVie Inches Closer to Acquiring Shire
Sweetened $53.6 billion offer gets UK biopharma to the negotiating table.
Blue Cross Moves Toward Value-Based Healthcare
Insurer spending $65 billion on programs that contract with doctors and hospitals for quality, outcomes and cost measures.
Nanotech Microchip to Diagnose Type 1 Diabetes
Stanford researchers develop inexpensive, portable test that can deliver rapid results.
Salix to Merge with Cosmo Tech in Tax Inversion Deal
Transaction broadens Salix’s GI offerings and gives it tax advantages of being headquartered in Ireland.
Cracking the Social Media Code
Podcast: July 14, 2014
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER